Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for American Well Corporation (Amwell) (NYSE: AMWL) brings together the company’s official regulatory disclosures, as filed with the U.S. Securities and Exchange Commission. These documents provide detailed information on Amwell’s financial reporting, material agreements and other significant corporate events related to its digital care and technology-enabled healthcare platform.
Among the key filings are Form 8‑K current reports, which Amwell uses to announce material events. Recent 8‑K filings include disclosures of quarterly financial results, with earnings reports furnished as exhibits and details on investor conference calls and webcasts. Other 8‑K filings describe material definitive agreements, such as amendments and statements of work with Elevance Health under which Amwell operates the LiveHealth Online white‑label digital care platform and receives annual subscription fees and related service fees.
Filings also outline amendments to provider agreements involving Online Care Group, P.C., Amwell’s clinical partner, which maintains a 50‑state network of clinical professionals delivering digital care consultations via the LiveHealth Online platform. These documents specify contract terms, renewal provisions and termination rights, offering insight into how Amwell structures long‑term partnerships that support its technology-enabled care services.
On Stock Titan, investors can use AI-powered tools to read and interpret Amwell’s SEC filings more efficiently. AI summaries highlight the main points of lengthy documents, explain the implications of material agreements and clarify the context of earnings-related disclosures. Real-time updates from EDGAR ensure that new 8‑K filings and other reports appear promptly, while structured access to exhibits helps users locate information on subscription arrangements, provider networks and other aspects of Amwell’s business.
For anyone analyzing AMWL, this page serves as a focused entry point into Amwell’s regulatory history, combining raw SEC documents with AI-generated explanations that make complex legal and financial language easier to understand.
American Well Corporation (Amwell) is asking stockholders to vote at its 2026 virtual annual meeting on electing two Class III directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive pay on an advisory basis. The proxy also reviews 2025 performance, highlighting a shift to a tech‑enabled care platform and stronger operating discipline. Amwell recorded 2025 total revenue of $249.3 million, including $132.4 million of subscription revenue and $94.3 million of AMG visit revenue, with a 53% gross margin. Net loss narrowed to ($95.0) million from ($212.6) million in 2024, and total visits reached 4.5 million. Year‑end cash and short‑term securities were about $182.3 million. Management reiterates a goal of achieving positive operating cash flow in 2026 and emphasizes its Defense Health Agency SaaS deployment, AI‑enabled programs, and corporate responsibility initiatives. The Board remains majority‑independent and classified, and Amwell is a NYSE “controlled company” through Class B voting shares held by its co‑founders.
American Well Corp executive Phyllis Gotlib, President, International, reported an automatic sale of 3,706 shares of Class A Common Stock on April 1, 2026 at $5.30 per share. The sale was a non-discretionary “sell to cover” to pay taxes on vested restricted stock units.
After this transaction, Gotlib holds 163,004 shares directly and 114,250 shares indirectly through her husband, indicating the sale was small relative to her overall position and primarily for tax obligations rather than portfolio rebalancing.
American Well Corp Chief Product & Tech. Officer Dmitry Zamansky reported an open-market sale of 5,575 shares of Class A Common Stock at $5.30 per share. The footnote explains the sale was an automatic “sell to cover” to pay taxes from restricted stock units vesting on April 1, 2026, and not a discretionary trade. Following this transaction, he directly holds 241,080 shares.
American Well Corp Chief Accounting Officer Paul Francis McNeice reported a small, non-discretionary stock sale. On April 1, 2026, he sold 383 shares of Class A Common Stock at $5.30 per share to cover tax liabilities from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 10,616 shares of American Well Corp.
American Well Corporation reports that board member Dr. Peter Slavin has notified the company he will resign from its Board of Directors, effective at the company’s next annual meeting of stockholders in 2026. He will continue to serve as a director until that meeting.
The company states that Dr. Slavin’s decision is due to his transition to a new role on the West Coast of the United States and is not the result of any disagreement regarding American Well’s operations, policies, or procedures. The company expresses appreciation for his more than nine years of board service.
American Well Corporation (AMWL) submitted a Form 144 notice reporting proposed transactions in Class A Common Stock tied to an RSU vesting event dated 04/01/2026. The filing lists share counts associated with the vesting and recent sales by Phyllis Gotlib on 01/02/2026 and 03/02/2026.
American Well Corporation filing a Form 144 shows 11,831 Class A common shares vested from a restricted stock unit grant on 04/01/2026 and discloses prior sales: 2,472 shares sold on 03/02/2026 for $14,090.40 and 6,243 shares sold on 01/02/2026 for $30,284.79.
HIRSCHHORN MARK reported acquisition or exercise transactions in this Form 4 filing.
American Well Corp reported that its Chief Financial Officer, Mark Hirschhorn, received an equity award tied to 50,413 shares of Class A common stock on March 4, 2026. The award was granted at no cash cost per share.
According to the footnote, this represents a grant of restricted stock units that will vest in equal quarterly installments over a two-year period, starting on the first calendar day of the month after three months from the grant date. Following this award, Hirschhorn directly holds 253,999 shares of Class A common stock.
American Well Corp executive Phyllis Gotlib reported an equity award of company stock. She acquired 50,413 shares of Class A Common Stock as a grant of restricted stock units with a stated price of $0.00 per share. Following this award, she directly holds 166,710 shares.
The RSUs will vest in equal quarterly installments over a two-year period, beginning on the first calendar day of the month after three months from the grant date and continuing until fully vested after 24 months. In addition, 114,250 shares are reported as indirectly owned through her husband.